Replies to post #243289 on Avid Bioservices Inc (CDMO)

[biopharm]

Projects
Antibody targeting of phosphatidylserine produces a cytokine microenvironment that enhances innate anti-tumor immune responses(Link)
April 2008

No. 4079: Monica L. Friedrich, Claudia I. Guevara, Daniel M. Falcon,
Longen Zhou, Connie Chang and Bruce Freimark, Antibody targeting of
phosphatidylserine produces a cytokine microenvironment that enhances innate anti-tumor immune responses, Peregrine Pharmaceuticals, Inc.

This yellow sticky fell off the board and just picking it back up... it has Fujifilm Diosynth Biotechnologies on it and leads back to Steve Bagshaw CEO of Fujifilm and ex-Zeneca (what is now AstraZeneca..)

Too many familiar names here, starting with Longhen Zhou and here we go again...

[biopharm]

Cristina Brinkmann know of Xencor and John Stafford .... this Astellas ...Agensys becomes more likely a direct collaboration with Peregrine Pharmaceuticals

[biopharm]

MRI images critically important so Fujifilm, we welcome you aboard with any offers you may have for investments as well : )

... Fujifilm Diosynth Biotechnologies ...

Cristina Brinkmann ex-Xencor and Peregrine.....and I say someone out of the box is required to Stryker a deal and no way they wait till Nov to bring more to the surface

Maybe John Madsen will force Fujifilms hand ....we shall see.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=131130377

[biopharm]

Peregrine and Fujifilm

"Their collective vision is to be the global biologics and vaccine CDMO partner of choice through continuous technology innovation, superior service, and commitment to quality. It is the strength and spirit of our leadership team that guides us in our daily mission to make a positive contribution to society by supporting the development of novel lifesaving treatments"

http://www.fujifilmdiosynth.com/who-we-are/leadership/

One would have an advantage of being that global CDMO leader with Avid ...

[biopharm]

Diosynth:

History

The company started in Oss, Netherlands[2] in 1923 with the extraction of insulin from bovine pancreas, and porcine insulin extraction in 1930, both of which are still part of their main products.[3][4][5] In January 2005, the company became a part of Organon, one of its sister companies in the Akzo Nobel pharma group.[6] Along with its sister companies Organon and Intervet were sold to Schering-Plough in March 2007 by Akzo Nobel.[7] Following the mergers of Schering-Plough with Merck & Co. (MSD) in March 9, 2009,[8] the company was part of the MSD Nutritionals products company, belonging to the MSD group.[9]

In April 2011, the company was sold to Fujifilm and Fujifilm Diosynth Biotechnologies was formed.
..
..

Very interesting, Gregory L. Conn of PDS Biotechnology was with Diosynth from 2000-2004 where the history with Merck was rooted strong and the case is building stronger that Ronin Hedge Group has Merck in mind to pass over PS Targeting for breadcrumbs...

https://www.linkedin.com/in/greg-conn-1480ba4

GREGORY L. CONN, PH.D.

CHIEF SCIENTIFIC OFFICER

B.S., Chemistry, M.S., Ph.D., Biochemistry — Albert Einstein College of Medicine, NY
Dr. Conn has more than 35 years of drug-development expertise, including development of antiviral and anticancer drugs through to commercialization. He is a graduate of the Albert Einstein College of Medicine, where he obtained both his M.S. and Ph.D., discovering novel angiogenic molecules in the human brain. Dr. Conn started his pharmaceutical career at Merck, Sharpe, and Dohme, where he continued his work on novel angiogenic factors, discovering and characterizing the VEGF family of growth factors, work which led to the development and commercialization of the anti-cancer drug Avastin. He was later a leading scientist at Regeneron Pharmaceuticals, where he established and headed various groups in the Cell and Molecular Biology and Drug Discovery departments. Dr. Conn subsequently became a Director in the Process Development department at Covance Biotechnology Services Inc., a contract research and development and drug manufacturing organization, where he supervised the analytical development teams responsible for drug characterization, method development and drug stability studies, and program teams responsible for developing drug manufacturing processes. Dr. Conn has expertise across all phases of the drug development process, including FDA and regulatory requirements, is the co-inventor of eight drug patents, and was a founding member of the PDS team as CSO.

http://pdsbiotech.com/about-us/management-team-2/

[biopharm]

Diosynth:

History

The company started in Oss, Netherlands[2] in 1923 with the extraction of insulin from bovine pancreas, and porcine insulin extraction in 1930, both of which are still part of their main products.[3][4][5] In January 2005, the company became a part of Organon, one of its sister companies in the Akzo Nobel pharma group.[6] Along with its sister companies Organon and Intervet were sold to Schering-Plough in March 2007 by Akzo Nobel.[7] Following the mergers of Schering-Plough with Merck & Co. (MSD) in March 9, 2009,[8] the company was part of the MSD Nutritionals products company, belonging to the MSD group.[9]

In April 2011, the company was sold to Fujifilm and Fujifilm Diosynth Biotechnologies was formed.

On December 18, 2014, Fujifilm Diosynth Biotechnologies acquired Kalon Biotherapeutic Technologies in College Station, TX, which became Fujifilm Diosynth Biotechnologies Texas, LLC.[11]

https://en.wikipedia.org/wiki/Diosynth


-------------------------

Digging deeper.... oh my.... some interesting names from the past


Quote:

Cristina Brinkmann

Scientist 1 at Fujifilm Diosynth Biotechnologies
Raleigh-Durham, North Carolina Area
Biotechnology

Current

Fujifilm Diosynth Biotechnologies

Previous

Xencor, Peregrine Pharmaceuticals, The Scripps Research Institute

Too many coincidences for me here.....time for Roger to decide how much longer the shenanigans go on in downplaying the value of the IP assets which are under his guidance of control as CEO and Fiduciary Duties must be watched very carefully now

[biopharm]

... Fujifilm Diosynth Biotechnologies

Quote:
Mri contrast medium containing liposomes

EP 1888124 A1 (text from WO2006132403A1)

Inventors
Junji c/o FUJIFILM CORPORATIOND.
NISHIGAKI, Hiroyuki c/o FujiFilm Corporation
HIRAI, Masayoshi c/o FujiFilm Corporation KOJIMA,
Kazuhiro c/o FUJIFILM CORPORATION AIKAWA,

Applicant FUJIFILM Corporation

Abstract
A liposome containing a phosphatidylcholine and a phosphatidylserine in combination as membrane components at a phosphatidylcholine:phosphatidylserine molar ratio of 3:1 to 1:2, and said liposome containing superparamagnetic particles having a mean particle size not less than 1 nm and not more than 50 nm. A means for selectively accumulating an MRI contrast medium in a lesion of a vascular disease caused by abnormal proliferation of vascular smooth muscle cells such as arteriosclerosis and restenosis after PTCA is provided.

https://www.google.com/patents/EP1888124A1?cl=en

Very difficult to argue with facts....and remember these patents re: Phosphatidylserine but now since the late Dr Phil Thorpe tageted flipped PS and patented it....we must consider the possibility that any and all BP ties (like that of Fuji Diosynth ...fka Covance) may present conflicts of interest for CEO Roger Lias which is possibly why he says "residual value"

Very interesting things developing now ...

[biopharm]

Mri contrast medium containing liposomes

EP 1888124 A1 (text from WO2006132403A1)

Inventors
Junji c/o FUJIFILM CORPORATIOND.
NISHIGAKI, Hiroyuki c/o FujiFilm Corporation
HIRAI, Masayoshi c/o FujiFilm Corporation KOJIMA,
Kazuhiro c/o FUJIFILM CORPORATION AIKAWA,

Applicant FUJIFILM Corporation

Abstract
A liposome containing a phosphatidylcholine and a phosphatidylserine in combination as membrane components at a phosphatidylcholine:phosphatidylserine molar ratio of 3:1 to 1:2, and said liposome containing superparamagnetic particles having a mean particle size not less than 1 nm and not more than 50 nm. A means for selectively accumulating an MRI contrast medium in a lesion of a vascular disease caused by abnormal proliferation of vascular smooth muscle cells such as arteriosclerosis and restenosis after PTCA is provided.

https://www.google.com/patents/EP1888124A1?cl=en


Did this biotech truly come out of Fujifilm?
....
...
...

Why would CEO Roger Lias not tell the truth and hide, conceal, blatantly distort the value that exists in the IP assets of PS Targeting?

No investment hired.....as of last cc and who knows, maybe they woke up and hired an Investment Bank to bring forth a very simple open market bidding type of system but do so with all PS Targeting trial data , collaboration data , non Disclosed collaboration data and we have all seen about 9 patents that disclose the important of Phosphatidylserine and one day it looks like MRIs and 3D imaging etc out of FujiFilm Diosynth "WILL" require some license rights because if one looks again at FujiFilm patents above ....

Sounds to me like the MRI depends upon flipped PS ratio of at least 3:1 and how incompetent is Renegade Roger Lias these days ?

How much more will shareholders take before reporting all they know to DOJ, FBI, SEC, FDA and again....Ronin Hedge Group was just another pawn in this ....as Dr Lias is.....but the CEO signing off a material event will have to answer some tough questions if required to do so and awfully quiet in Tustin ....are they not using corporate phones these days for official business ....hmmmm

[biopharm]

Has anyone seen the relevance now with FujiFilm and Eli Lilly in PS Targeting IP and in sum, research data that concludes the PS Targeting IP assets of Peregrine Pharmaceuticals ..now called Avid Bioservices, partially transferred to Oncologie with Eli Lilly ....

I wonder why Ronin Hedge Group services were required it seems and all beginning to become very clear ...how the true value of the IP is much higher

[biopharm]

MRI images critically important so Fujifilm, we welcome you aboard with any offers you may have for investments as well : )

... Fujifilm Diosynth Biotechnologies




Patent info: Mri contrast medium containing liposomes

EP 1888124 A1 (text from WO2006132403A1)

Inventors
Junji c/o FUJIFILM CORPORATIOND.
NISHIGAKI, Hiroyuki c/o FujiFilm Corporation
HIRAI, Masayoshi c/o FujiFilm Corporation KOJIMA,
Kazuhiro c/o FUJIFILM CORPORATION AIKAWA,

Applicant FUJIFILM Corporation

Abstract
A liposome containing a phosphatidylcholine and a phosphatidylserine in combination as membrane components at a phosphatidylcholine:phosphatidylserine molar ratio of 3:1 to 1:2, and said liposome containing superparamagnetic particles having a mean particle size not less than 1 nm and not more than 50 nm. A means for selectively accumulating an MRI contrast medium in a lesion of a vascular disease caused by abnormal proliferation of vascular smooth muscle cells such as arteriosclerosis and restenosis after PTCA is provided.

https://www.google.com/patents/EP1888124A1?cl=en

Did this biotech truly come out of Fujifilm?
...
...

We have a little more time here to see what type of credits Fujifilm will give to PS Targeting IP since it is clear that PS Targeting is important to them

[biopharm]

Mri contrast medium containing liposomes

There have been lots of Targeting of flipped PS and one being
"Avid Radiopharmaceuticals"...
which would fit in nicely with Avid Bioservices since many things in common

Eli Lilly is the parent company of Avid Radiopharmaceuticals

Manufacturing rights must be astronomical for PS Targeting since all the collaborations with Merck Lilly friends chose the path to wait ...for one like John Springs Stafford to play dumb on PS Targeting valuations